Home›Clinical trials›Minnesota

GLP-1 clinical trials in Minnesota: 17 recruiting now

By John Samaras, EditorRegistry checked September 4, 2026

17 GLP-1 clinical trials are recruiting at 22 sites in 5 cities across Minnesota. Every site below is listed with its city and, where the sponsor publishes one, the number to call.

Every study recruiting in Minnesota

  1. PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

    Phase 4. Run by Brigham and Women's Hospital. Registry number NCT05390892.

    A study testing whether a GLP-1 medicine, semaglutide, can help people lower blood sugar.

    Who can join. Adults 40 to 80, have type 2 diabetes.

    2 sites in Minnesota

  2. Fibrosis Lessens After Metabolic Surgery

    Phase 4. Run by The Cleveland Clinic. Registry number NCT06374875.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people reduce liver fat.

    Who can join. Adults 18 to 75, have fatty liver disease (MASLD) with liver scarring (fibrosis), BMI 35+.

    1 site in Minnesota

    • Mayo Clinic, Rochester

  3. Tirzepatide in PWS, HO and GNSO

    Phase 4. Run by Grace Kim. Registry number NCT06901245.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people with Prader-Willi syndrome lose weight.

    Who can join. Adults 18 to 26, have Prader-Willi syndrome, BMI 30+.

    1 site in Minnesota

  4. Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder

    Phase 4. Run by Mayo Clinic. Registry number NCT07213466.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with bipolar I disorder lose weight.

    Who can join. Adults 18 to 65, have bipolar I disorder, BMI 27+.

    1 site in Minnesota

  5. A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity

    Phase 4. Run by Gila Therapeutics, Inc. Registry number NCT07728383.

    A study testing whether a GLP-1 medicine, semaglutide, can help people lose weight.

    Who can join. Adults 18 to 65, have obesity or are overweight, BMI 30+.

    1 site in Minnesota

    • Clinical Research Institute of Minnesota, Minneapolis. 612-333-2200

  6. A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

    Phase 3. Run by Eli Lilly and Company. Registry number NCT06672549.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lose weight.

    Who can join. Children and teens 6 to 17, have obesity.

    3 sites in Minnesota

    • University of Minnesota Masonic Children's Hospital, Minneapolis
    • Mayo Clinic - PIN, Rochester
    • Children's Minnesota Pediatric Endocrinology Clinic & McNeeley Diabetes Center, Saint Paul

  7. A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

    Phase 3. Run by Novo Nordisk A/S. Registry number NCT07253285.

    A study testing whether a study medicine from Novo Nordisk, cagrilintide, can help people lose weight.

    Who can join. Children and teens 8 to 18, are overweight.

    2 sites in Minnesota

    • University of Minnesota, Minneapolis
    • Synexus Clinical Research US-MN, Richfield

  8. A Clinical Study to Compare Efficacy and Safety of Two Different Doses of CagriSema and Semaglutide in Participants With Obesity

    Phase 3. Run by Novo Nordisk A/S. Registry number NCT07564414.

    A study testing whether a study medicine from Novo Nordisk, cagrisema, can help people with type 2 diabetes lose weight.

    Who can join. Adults 18+, have obesity, BMI 35+.

    2 sites in Minnesota

    • International Diabetes Center, Minneapolis
    • AES Minneapolis DRS, Richfield

  9. LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced

    Phase 3. Run by Boehringer Ingelheim. Registry number NCT06632444.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH) with liver scarring (fibrosis).

    1 site in Minnesota

  10. LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

    Phase 3. Run by Boehringer Ingelheim. Registry number NCT06632457.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH), BMI 25+.

    1 site in Minnesota

  11. A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

    Phase 3. Run by Eli Lilly and Company. Registry number NCT07165028.

    A study testing whether a GLP-1, GIP and glucagon medicine from Lilly, retatrutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (MASLD), BMI 25+.

    1 site in Minnesota

    • MNGI Digestive Health, Minneapolis

  12. Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE)

    Phase 3. Run by VA Office of Research and Development. Registry number NCT07218354.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with alcohol use disorder drink less.

    Who can join. Adults 18 to 80, have alcohol use disorder, BMI 21+.

    1 site in Minnesota

    • Minneapolis VA Health Care System, Minneapolis, MN, Minneapolis. 6124671580

  13. A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron

    Phase 3. Run by AstraZeneca. Registry number NCT07662213.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    1 site in Minnesota

    • Research Site, Minneapolis

  14. A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

    Phase 3. Run by Boehringer Ingelheim. Registry number NCT07754461.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    1 site in Minnesota

  15. The Role of Islet GLP-1 in the Pathogenesis of Prediabetes

    Phase 2. Run by Mayo Clinic. Registry number NCT06967558.

    A study testing whether a study medicine can help people with prediabetes lower blood sugar.

    Who can join. Adults 25 to 70, have prediabetes.

    1 site in Minnesota

  16. The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes

    Phase 2. Run by Mayo Clinic. Registry number NCT06976619.

    A study testing whether a GLP-1 medicine, liraglutide, can help people with type 1 diabetes lower blood sugar.

    Who can join. Adults 25 to 70, have type 1 diabetes.

    1 site in Minnesota

  17. Effect of Prolonged Fasting Time on Gastric Residual Volume in Patients Taking GLP1 Receptor Agonists

    Run by Mayo Clinic. Registry number NCT07006142.

    A study listed on ClinicalTrials.gov.

    1 site in Minnesota

Source: ClinicalTrials.gov, the federal registry, read September 4, 2026. Open a study's registry record before you call: it can close to new participants at any time. GLP Chart does not enroll anyone, is not paid for clinical-trial referrals and has no relationship with any sponsor or site on this page.

Screening for a study can take weeks. If you need the drug now, Strut Health is the cheapest cash route on the chart, from $149 a month. That price buys compounded semaglutide, a pharmacy-made version that is not FDA-approved and is not Wegovy, Ozempic, Zepbound or Mounjaro.

Visit Strut Health ↗

Clinical trials by state

Every state with a GLP-1 study recruiting today. 48 of them.

John Samaras, editor of GLP Chart
John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this siteLinkedInContact
Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.